U01CA233167
Cooperative Agreement
Overview
Grant Description
Understanding treatment tolerability in older patients with cancer.
Awardee
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
New York
United States
Geographic Scope
State-Wide
Related Opportunity
Analysis Notes
Amendment Since initial award the End Date has been extended from 08/31/23 to 08/31/25 and the total obligations have increased 439% from $649,295 to $3,500,218.
University Of Rochester was awarded
Understanding Treatment Tolerability in Older Patients with Cancer
Cooperative Agreement U01CA233167
worth $3,500,218
from National Cancer Institute in September 2018 with work to be completed primarily in New York United States.
The grant
has a duration of 7 years and
was awarded through assistance program 93.353 21st Century Cures Act - Beau Biden Cancer Moonshot.
The Cooperative Agreement was awarded through grant opportunity Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability (U01).
Status
(Ongoing)
Last Modified 9/20/24
Period of Performance
9/20/18
Start Date
8/31/25
End Date
Funding Split
$3.5M
Federal Obligation
$0.0
Non-Federal Obligation
$3.5M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for U01CA233167
Transaction History
Modifications to U01CA233167
Additional Detail
Award ID FAIN
U01CA233167
SAI Number
U01CA233167-1281117534
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75NC00 NIH NATIONAL CANCER INSTITUTE
Funding Office
75NC00 NIH NATIONAL CANCER INSTITUTE
Awardee UEI
F27KDXZMF9Y8
Awardee CAGE
03CZ7
Performance District
NY-90
Senators
Kirsten Gillibrand
Charles Schumer
Charles Schumer
Budget Funding
Federal Account | Budget Subfunction | Object Class | Total | Percentage |
---|---|---|---|---|
National Cancer Institute, National Institutes of Health, Health and Human Services (075-0849) | Health research and training | Grants, subsidies, and contributions (41.0) | $2,957,353 | 100% |
Modified: 9/20/24